B07 | LONG-TERM CLINICAL OUTCOMES WITH TISAGENLECLEUCEL IN HIGH-RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: 4-YEAR FOLLOW-UP FROM THE PHASE 2 ELARA STUDY

Background: Treatment approach for relapsed/refractory follicular lymphoma (r/r FL) depends on previous treatments and patients’ characteristics. Tisagenlecleucel is a Chimeric Antigen Receptor T-cell therapy (CAR-T) approved for adults with r/r FL after at least two prior lines of systemic therapy...

Descripción completa

Detalles Bibliográficos

Autores principales:	P.L. Zinzani, C. Thieblemont, M. Dreyling, M.J. Dickinson, J. Martínez-Lopez, A. Kolstad, J. Butler, M. Ghosh, L.L. Popplewell, J.C. Chavez, E. Bachy, K. Kato, H. Harigae, M.J. Kersten, C. Andreadis, P.A. Riedell, P.J. Ho, J.A. Pérez-Simón, A. Chen, L. Nastoupil, B. Von Tresckow, A.J.M. Ferreri, T. Teshima, P.E.M. Patten, J.P. Mcguirk, F. Offner, A. Viardot, R. Malladi, A. Zia, R. Awasthi, D. Germano, R.J. Ramos, P. Hsu, S.J. Schuster, N.H. Fowler
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Ferrata Storti Foundation 2025-09-01
Colección:	Haematologica
Acceso en línea:	https://haematologica.org/article/view/12859
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!